Showing results (191-200 of 256) with videos related to

Sort By:
Pageof 26
Annals of the Rheumatic Diseases|October 14, 2004
Long term high intensity exercise and damage of small joints in rheumatoid arthritisZ de Jong, M Munneke, A H Zwinderman, et al.
Rheumatology (Oxford, England)|April 11, 2008
Value of serum cartilage oligomeric matrix protein as a prognostic marker of large-joint damage in rheumatoid arthritis--data from the RAPIT studyZ de Jong, M Munneke, V Vilim, et al.
Annals of the Rheumatic Diseases|August 5, 2005
Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritisM M J Nielen, D van Schaardenburg, H W Reesink, et al.
Annals of the Rheumatic Diseases|May 10, 2011
Simplified versions of the original disease activity score: validation in the BeSt trialR Koevoets, N B Klarenbeek, M Güler-Yüksel, et al.
Arthritis and Rheumatism|April 1, 2011
Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort studyL A Korswagen, G M Bartelds, C L M Krieckaert, et al.
Arthritis and Rheumatism|August 31, 2004
Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritisMarkus M J Nielen, Dirkjan van Schaardenburg, Henk W Reesink, et al.
Investigational New Drugs|February 15, 2018
Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptideRuud Oerlemans, Celia R Berkers, Yehuda G Assaraf, et al.
Osteoarthritis and Cartilage|August 10, 2010
Treatment with TNF-α inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritisM Güler-Yüksel, C F Allaart, I Watt, et al.
Annals of the Rheumatic Diseases|May 1, 2008
Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritisW H Bos, G M Bartelds, M Vis, et al.
Annals of the Rheumatic Diseases|March 30, 2011
Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritisSaskia Vosslamber, Hennie G Raterman, Tineke C T M van der Pouw Kraan, et al.
Pageof 26